Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer

Mothaffar F. Rimawi(Baylor College of Medicine), Rachel Schiff(Baylor College of Medicine), Matthew P. Goetz(Mayo Clinic), Carolina Gutiérrez(Baylor College of Medicine), Jenny C. Chang(Baylor College of Medicine), Antonio C. Wolff(Johns Hopkins University), Carmine De Angelis(Baylor College of Medicine), Sabrina Herrera(Mayo Clinic), Alejandro Contreras(Baylor College of Medicine), C. Kent Osborne(Baylor College of Medicine), Ian E. Krop(Yale Cancer Center), Britta Weigelt(Memorial Sloan Kettering Cancer Center), Andres Forero(University of Alabama at Birmingham), Felipe C. Geyer(Memorial Sloan Kettering Cancer Center), Suzanne A.W. Fuqua(Baylor College of Medicine), Kathleen A. Burke(Memorial Sloan Kettering Cancer Center), Ingrid A. Mayer(Vanderbilt University), Susan G. Hilsenbeck(Baylor College of Medicine), Jorge S. Reis‐Filho(Institute of Cancer Research), Marilyn M. Li(Children's Hospital of Philadelphia), Anne C. Pavlick(Baylor College of Medicine), Fresia Pareja(Memorial Sloan Kettering Cancer Center), Tao Wang(Fujian University of Traditional Chinese Medicine), Rita Nanda(University of Chicago)
Breast Cancer Research and Treatment
November 7, 2017
Cited by 95


Related Papers